Neuromuscular diseases (NMDs) encompass a broad spectrum of conditions. Because infections may be relevant to the final prognosis of most NMDs, vaccination appears to be the simplest and most effective solution for protecting NMD patients from vaccine-preventable infections. However, very few studies have evaluated the immunogenicity, safety, tolerability, and efficacy of different vaccines in NMD patients; therefore, detailed vaccination recommendations for NMD patients are not available. Here, we present vaccination recommendations from a group of Italian Scientific Societies for optimal disease prevention in NMD patients that maintain high safety levels. We found that NMD patients can be classified into two groups according to immune function: patients with normal immunity and patients who are immunocompromised, including those who intermittently or continuously take immunosuppressive therapy. Patients with normal immunity and do not take immunosuppressive therapy can be vaccinated as healthy subjects. In contrast, immunocompromised patients, including those who take immunosuppressive therapy, should receive all inactivated vaccines as well as influenza and pneumococcal vaccines; these patients should not be administered live attenuated vaccines. In all cases, the efficacy and long-term persistence of immunity from vaccination in NMD patients can be lower than in normal subjects. Household contacts of immunocompromised NMD patients should also be vaccinated appropriately.

Vaccination recommendations for patients with neuromuscolar disease / S. Esposito, C. Bruno, A. Bernardelli, M. Filosto, T. Mongini, L. Morandi, O. Musumeci, E. Pegoraro, G. Siciliano, P. Tonin, G. Marrosu, C. Minetti, M. Servida, C. Fiorillo, G. Conforti, S. Scapolan, F. Ansaldi, A. Vianello, S. Castaldi, N. Pincipi, A. Toscano, M. Moggio. - In: VACCINE. - ISSN 0264-410X. - 32:45(2014), pp. 5893-5900.

Vaccination recommendations for patients with neuromuscolar disease

S. Esposito;S. Castaldi;
2014

Abstract

Neuromuscular diseases (NMDs) encompass a broad spectrum of conditions. Because infections may be relevant to the final prognosis of most NMDs, vaccination appears to be the simplest and most effective solution for protecting NMD patients from vaccine-preventable infections. However, very few studies have evaluated the immunogenicity, safety, tolerability, and efficacy of different vaccines in NMD patients; therefore, detailed vaccination recommendations for NMD patients are not available. Here, we present vaccination recommendations from a group of Italian Scientific Societies for optimal disease prevention in NMD patients that maintain high safety levels. We found that NMD patients can be classified into two groups according to immune function: patients with normal immunity and patients who are immunocompromised, including those who intermittently or continuously take immunosuppressive therapy. Patients with normal immunity and do not take immunosuppressive therapy can be vaccinated as healthy subjects. In contrast, immunocompromised patients, including those who take immunosuppressive therapy, should receive all inactivated vaccines as well as influenza and pneumococcal vaccines; these patients should not be administered live attenuated vaccines. In all cases, the efficacy and long-term persistence of immunity from vaccination in NMD patients can be lower than in normal subjects. Household contacts of immunocompromised NMD patients should also be vaccinated appropriately.
Chronic disease; Immunocompromised patients; Influenza vaccination; Neurologic disease; Neuromuscular disease; Pneumococcal vaccine
Settore MED/26 - Neurologia
Settore MED/38 - Pediatria Generale e Specialistica
Settore MED/42 - Igiene Generale e Applicata
2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0264410X14012353-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 698.28 kB
Formato Adobe PDF
698.28 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/248546
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 16
social impact